Glycosylation and the Demands of Antibody Engineering - Roy Jefferis examines precise questions about how sugars drive antibody function. - BioPharm International

ADVERTISEMENT

Glycosylation and the Demands of Antibody Engineering
Roy Jefferis examines precise questions about how sugars drive antibody function.


BioPharm International
Volume 20, Issue 10

KJM: Do you foresee a lot of advances in fundamental and applied glycosylation science on the horizon?

RJ: These developments can be anticipated to have a significant impact on antibody performance and ultimately on the cost of goods. They will also be applied for the improvement of other biologics. Thus, glycosylation has profound effects on the performance of erythropoietin (EPO). Amgen has recognized this and has re-engineered the molecule to introduce two extra glycosylation sites. The product has improved biologic efficacy and a longer half-life.

The next challenge is the development of biosimilars and competition in the marketplace resulting in a lowering of costs. Competition will come from low-cost economies; even if not licensed within the US, they will compete since they will be available from the web.

K. John Morrow, Jr., PhD, is the president of Newport Biotech, Newport, KY, 513.237.3303;


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Novartis Reports Positive Results for Secukinumab in Ankylosing Spondylitis Trials
October 23, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Author Guidelines
Source: BioPharm International,
Click here